急性脑梗死应用阿替普酶治疗不同年龄段的疗效及预后的相关性研究

A study on the relationship between the curative effect and prognosis of patients with acute cerebral infarction treated with ateppase in different ages

目的急性脑梗死应用阿替普酶治疗不同年龄段的疗效及预后的相关性研究。方法选取2018年1月至2018年10月本院接诊的急性脑梗死应用阿替普酶治疗的患者96例为研究对象,按照年龄的不同分成低龄组(60岁以下)44例与老龄组(60岁及以上)52例。对两组临床资料、治疗效果、预后情况等进行比较。结果治疗3周后,低龄组NIHSS评分(3.12±1.05)分,mRS评分(1.02±0.75)分,老龄组NIHSS评分(5.69±1.73)分,mRS评分(2.26±0.19)分,比较差异具有统计学意义(P<0.05)。跟踪随访临床预后,低龄组预后良好率86.36%,老龄组预后良好率67.31%,比较差异具有统计学意义(P<0.05)。低龄组治疗有效率97.73%,老龄组治疗有效率88.46%,比较差异具有统计学意义(P<0.05)。结论急性脑梗死应用阿替普酶治疗低龄组治疗效果以及预后情况均优于老龄组,在高龄急性脑梗死患者应用阿替普酶治疗中应进一步进行综合评估,提高治疗及预后效果。

Objective To study the correlation between the efficacy and prognosis of acute cerebral infarction treated with alteplase in different age groups. Methods A total of 96 patients with acute cerebral infarction treated with alteplase from January 2018 to October 2018 were selected as subjects. The patients were divided into the younger group(under 60 years old) with 44 cases and the elderly group(60 years old and above) with 52 cases according to their ages. The clinical information, treatment effect and prognosis of the two groups were compared. Results After 3 weeks of treatment, the NIHSS score(3.12±1.05) scores and mRS score(1.02±0.75) scores in the younger age group, the NIHSS score(5.69±1.73) scores and the mRS score(2.26±0.19) scores in the old age group, the difference was statistically significant(P<0.05). The clinical prognosis was followed up.The prognosis rate was 86.36% in the younger age group and 67.31% in the old age group, the difference was statistically significant(P<0.05). The effective rate of treatment was 97.73% in the younger age group and 88.46% in the old age group, the difference was statistically significant(P<0.05).Conclusion The treatment effect and prognosis of acute cerebral infarction treated with alteplase in the younger age group are better than those in the old age group. In the treatment of elderly patients with acute cerebral infarction, alteplase should be further evaluated to improve the treatment and prognosis.